Docs Who Lift

In this episode of Docs Who Lift, the Nadolsky brothers dive deep into the newly released American Association of Clinical Endocrinology (ACE) Algorithm for Obesity Care led by Dr. Karl himself. They explore:Why ACE moved away from a BMI-only approach to a person-centered, complication-centric modelThe new staging framework (ABCD) that helps individualize treatment intensityHow to interpret “clinical” vs “preclinical” obesity under the new modelUpdated targets for clinically meaningful weight loss (5%, 10%, 15% tiers)The emphasis on resistance training, sleep, and behavioral health alongside nutritionPractical guidance for selecting anti-obesity medications and identifying the right therapy for each patientWhether you’re a clinician, health professional, or patient trying to understand modern obesity care, this episode breaks it all down in a practical, real-world way without the jargon.Youtube Video to follow along the graphic mentioned Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

TakeawaysThe book aims to dispel myths surrounding the Biggest Loser study.Miscommunication in media has led to public confusion about metabolism.Metabolic adaptation is a response to weight loss, not a determinant of it.Cultural factors significantly influence eating habits and food choices.The food environment plays a crucial role in dietary behaviors.Bipartisan support is necessary for effective food policy changes.Understanding metabolism requires a nuanced approach beyond just calories.The relationship between exercise and metabolism is complex and not fully understood.Appetite signals are a major factor in weight regain after dieting.Education about nutrition science is essential for public understanding.Julia Belluz X/TwitterKevin Hall X/TwitterPurchase Their Book Here  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways Menopausal women often prioritize weight gain concerns over other symptoms.The study observed an association between hormone therapy and weight loss with GLP-1 medications.Retrospective studies have limitations but can provide valuable insights.Future research should focus on randomized controlled trials to confirm findings.The relationship between estrogen and GLP-1 signaling needs further exploration.Funding for research can be challenging, especially for early career investigators.Collaboration between different specialties is crucial for comprehensive patient care.The media often misrepresents research findings, leading to misconceptions.Individualized treatment plans are essential for menopausal women.There is a need for more awareness about the effects of menopause on health.Research Links:Weight loss response to semaglutide in postmenopausal women with and without hormone therapy useCombination of obesity medication tirzepatide and menopause hormone therapy fuels weight loss   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

We covered:Fasted trainingProtein timingand many more fitness topics!Hear Dr. Lauren Colenso-Semple and Dr. Stacy Sims discuss outcomes versus mechanisms and much moreTap Here for Dr Stacy Sims ReferencesTap Here for Dr. Colenso-Semples ReferencesDr. LCS InstagramDr. SS Instagram  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

TakeawaysThe podcast features Dr. Grant Tinsley, a body composition expert.The discussion revolves around a case series on body composition effects.GLP-1 receptor agonists are a focus of the research.The importance of resistance training in weight loss is emphasized.Patient case studies provide insights into individual experiences.The first patient lost a significant amount of fat mass while preserving lean mass.The second patient achieved remarkable body composition changes in a short time.The third patient showed positive changes over a longer duration.The need for more randomized trials is highlighted.The conversation underscores the role of exercise and nutrition in weight management.Tap or Click here to see more from Dr. GrantTap here for scientific references in this episode. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

TakeawaysDirect-to-consumer lab testing is on the rise, with significant marketing efforts behind it.Many patients feel brushed off by traditional healthcare providers, leading them to seek alternative testing options.Communication between patients and healthcare providers is often inadequate, contributing to misunderstandings about health.Over-testing can lead to unnecessary anxiety and misinterpretation of results.Fitness influencers often promote lab testing without proper medical training, which can be harmful.There is a need for ethical practices in lab testing and patient care.Patients should be cautious of companies that upsell supplements based on lab results.The healthcare system often fails to provide adequate time for patient concerns to be addressed.Understanding lab results requires skilled interpretation, which is often lacking in direct-to-consumer models.A collaborative approach among healthcare professionals is necessary to improve patient outcomes.Click to join Dr. Spencer's online clinic if you need help with this  Click here to check out Barbell Medicine Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Dr. Lift podcast, hosts Dr. Spencer Nadolsky and Dr. Karl discuss the recent changes in obesity medication coverage, particularly focusing on the CVS Caremark decision to drop ZEPBound from their formulary in favor of Wegovi. They explore the implications of this decision for patients and providers, the role of pharmacy benefit managers (PBMs) in healthcare, and the ongoing advocacy efforts to ensure access to effective obesity treatments. The conversation highlights the complexities of insurance coverage, the need for patient-centered care, and the importance of making medications more affordable.- The recent changes in obesity medication coverage have raised concerns among providers and patients.- CVS Caremark's decision to drop ZEPBound has sparked a petition advocating for better access to medications.- Pharmacy Benefit Managers (PBMs) play a significant role in determining medication coverage and costs.- There is a need for more nuanced insurance policies that consider patient needs and clinical severity.- Advocacy efforts are crucial in reversing negative trends in medication coverage.- Patients often face challenges with prior authorization processes when switching medications.- The cost of obesity medications is a significant barrier to access for many patients.- Insurance companies are increasingly dropping coverage for anti-obesity medications, impacting patient care.- The conversation emphasizes the importance of patient-centered care in obesity treatment.- There is a call for making obesity medications more affordable and accessible to patients.https://www.change.org/p/stop-cvs-caremark-s-zepbound-ban-restore-coverage-of-the-superior-obesity-medicationClick to join Dr. Spencer's online clinic if you need help with this  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of the Dr. Lift podcast, hosts Dr. Spencer Nadolsky and Dr. Karl discuss the Surpass CVOT trial, which evaluates the cardiovascular outcomes of Monjaro compared to Dulaglutide (Trulicity). They delve into the significance of the trial, the implications of the results, and the potential benefits of Monjaro for patients with type 2 diabetes and cardiovascular risks. The conversation highlights the importance of understanding cardiovascular outcome trials and the evolving landscape of diabetes medications.Takeaways: The Surpass CVOT trial compares Mounjaro to Dulaglutide.Dulaglutide has shown cardiovascular benefits in previous trials.The trial results indicate Monjaro is at least not inferior to Dulaglutide.There is a trend towards better cardiovascular outcomes with Mounjaro.Weight loss and glycemic control are significant benefits of Mounjaro.The trial did not include a placebo, but used a putative analysis.The results are reassuring for patients at high cardiovascular risk.The conversation emphasizes the importance of comprehensive treatment for metabolic diseases.The hosts express enthusiasm for the potential of Mounjaro.Future discussions will delve deeper into the trial's findings.       Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How the STEP-UP trial came to life,  and what made the 7.2mg dose possibleWhat the data actually says about weight loss and side effects at higher dosesWhy trial design, pharmacokinetics, and estimands matter more than you thinkWhat’s coming next in obesity meds: duals, triples, and even antagonistsThe real talk on intermittent fasting, access issues, and preaching vs. scienceSign up for Dr. Spencer''s Clinic Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

TakeawaysThe study examines the overlap between clinical and anthropometric obesity.Anthropometric measures include waist circumference, waist-to-hip ratio, and BMI.Challenges exist in applying the Lancet Commission's definitions in clinical practice.Metabolically healthy obesity is a debated topic in obesity research.The study highlights the importance of data from the All of Us Research Program.There is a significant prevalence of preclinical obesity in individuals with normal BMI.The classification of obesity may need to shift focus towards overweight individuals.The study's findings suggest a need for more nuanced definitions of obesity-related diseases.Future research will explore the transition from preclinical to clinical obesity.The conversation emphasizes the importance of real-world data in understanding obesity.Click here to see the studyFollow Dr. Yao on X hereFollow Dr. Blaha on X here Click here to join Dr. Spencer's online clinic   Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Learn what age-related macular degeneration (AMD) isWhat causes AMDThe types of AMDThe update on NAION - listen to last year's podcast all about itWhy we aren't too concernedClick here to join Dr. Spencer's online clinic VineyardClick to read the JAMA AMD articleClick to read the Ophthalmology journal AMD article Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Menopausal hormonal therapy should not be a blanket recommendation for everyone going through menopauseWeight management in women is influenced by hormonal changes throughout life stages.Retrospective analyses can provide insights but have limitations.The wellness industry often oversimplifies complex medical issues.Hormonal replacement therapy may have subtle benefits for weight management.Confounding factors like SSRIs can complicate weight loss efforts.A holistic approach is essential for managing women's health during menopause.Education and awareness are crucial for women navigating menopause.Future research should focus on randomized controlled trials for better clarity.Understanding individual patient experiences is key to effective treatment.Click here to see her studyClick here to follow Dr. Tchang on XClick here to join Dr. Spencer's clinic Vineyard  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Grant Tinsley joins the discussion as the body composition expert.Myostatin is a key regulator of muscle growth.Wendy Whippete the most jacked muscled up dogThe concern of GLP-1 receptor agonists and muscle mass loss.Overview of Courage trial looking at semaglutide and trevogrumab and lean mass lossUpcoming Believe trial coming out (bimagrumab and semaglutide)Exercise remains crucial for muscle health and function.MRI data from SURPASS MRI provides new insights into muscle volume changes.The combination of medications may have varying effects on muscle mass.Caution is advised regarding the long-term effects of new drugs.Clinical benefits of medications often outweigh concerns about muscle loss.Future research will explore the synergy between exercise and medication.Other docs who lift podcasts with Dr. Grant:Tirzepatide muscle lossLean mass loss and GLP-1 meds Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Takeaways:The MAHA report aims to address public health issues but lacks actionable policies.Historical context is crucial for understanding current dietary guidelines.Funding for nutrition research has been inadequate, impacting the quality of data.Public perception of nutrition often outpaces scientific evidence.The evolution of dietary guidelines reflects political and social influences.There is a need for more rigorous nutrition science to inform policy.The dietary guidelines have not significantly improved population health metrics.Political will is essential for implementing effective nutrition policies.Nutrition science faces challenges in funding and research infrastructure.The MAHA report's recommendations may be more performative than substantive. Food policy changes are often superficial and ineffective.There is a significant disconnect between policy and actual health outcomes.Nutrition science is underfunded and lacks high-quality research.Misinformation in nutrition can lead to harmful public health outcomes.The focus on food additives distracts from more pressing issues like obesity.Experts are being sidelined in favor of political agendas.Public trust in health recommendations has eroded post-COVID.Nutrition policies need to be based on solid scientific evidence.The food industry needs clearer guidance on reformulating products.Future nutrition policies must prioritize public health over political gainRead Dr. Kevin's paperFollow Dr. Kevin on instagramJoin Dr. Spencer's clinic Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Click to read Joy PrescriptionsDrs. Karl and Spencer talk to Dr. Tiffany Moon all about Joy Prescriptions. Learn how to stop chasing perfection and embrace connection. 00:00Introduction to Dr. Tiffany Moon02:02Journey to Reality TV: The Real Housewives of Dallas05:58Life After Reality TV: Finding Joy and Purpose09:59The Joy Prescription: A New Approach to Life17:01Work-Life Integration: Balancing Career and Family22:09Empowering Women: The Lead Her Summit22:33Tiffany's Journey: From Childhood to Medical Success24:43The Quest for Joy: Breaking the Hedonic Treadmill26:42Finding Gratitude and Connection in Life28:37Coping Mechanisms: Humor and Self-Reflection29:57The Joy Prescription: A Path for High Achievers32:29Reconstructing Identity: Beyond External Validation35:37The Impact of Sports on Identity and Achievement40:54Closing Thoughts: Embracing Joy and Connection Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Tirzepatide is more effective for weight loss than semaglutide.Cost-effectiveness is crucial in prescribing weight loss medications.Patients with severe obesity should receive more expensive medications for better outcomes.Both medications show significant benefits for obesity-related conditions.Long-term studies indicate sustained weight loss with both drugs.Gender differences affect weight loss outcomes with these medications.Safety profiles show tirzepatide may be better tolerated than semaglutide.The need for affordable drug pricing is emphasized.Clinical benefits extend beyond weight loss to include metabolic health.Future studies are needed to confirm cardiovascular benefits of tirzepatide.Click here to see the studyClick here to join Dr. Spencer's new online clinic Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

TakeawaysMASH is a significant obesity-related complication.Semaglutide shows promise in treating MASH.Weight loss is crucial for improving liver health.Bariatric surgery remains the most effective treatment.The Essence trial indicates a 63% resolution of NASH.New medications are being developed for obesity treatment.Early intervention is key to preventing severe liver damage.Accessibility of medications is a major concern.Comparative studies are essential for evaluating new treatments.Future treatments may include innovative delivery methods.Chapters00:00 Introduction to MASH and Semaglutide Study04:29 Understanding Metabolic Dysfunction and Its Implications08:02 Essence Trial: Semaglutide's Impact on MASH12:58 Comparative Analysis of New Treatments for MASH17:30 The Future of Obesity Treatment and Drug AccessibilityJoin Vineyard - Dr. Spencer's online clinicSee the study Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs. Karl and Spencer chat with return guest Dr. Lauren Semple about creatine, protein, cortisol, fasting exercise, and training in women.Follow Dr. Lauren's instagramJoin Dr. Spencer's online clinic Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs. Karl and Spencer discuss a new study looking at tirzepatide and metabolic rate. They also discuss a patient case of tirzepatide induced anhedonia.Here is the tirzepatide studyIf interested in joining Dr. Spencer's clinic Vineyard - Click Here  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Drs. Karl and Spencer discuss the claim that GLP-1 meds cause more fat cells.Learn about if and how GLP-1 meds increase fat cells and what that means along with other claims about these medicine.Join Dr. Spencer's online clinic that specializes in GLP-1 medicines Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.